Jim Cramer: 'Hold On' To Builders FirstSource, 'Here's The Problem' With Viking Therapeutics

On CNBC’s "Mad Money Lightning Round," Jim Cramer said Vertex Pharmaceuticals Incorporated VRTX is "great."

On Aug. 1, Vertex Pharmaceuticals reported second-quarter revenues of $2.65 billion, almost in line with the consensus of estimate of $2.66 billion. Vertex raised its 2024 product revenue guidance from $10.55 billion-$10.75 billion to $10.65 billion-$10.85 billion.

Trending Now: 

• This billion-dollar fund has invested in the next big real estate boom, here's how you can join for $10.
  This is a paid advertisement. Carefully consider the investment objectives, risks, charges and expenses of the Fundrise Flagship Fund before investing. This and other information can be found in the Fund's prospectus. Read them carefully before investing.
• A billion-dollar investment strategy with minimums as low as $10 — you can become part of the next big real estate boom today.
  This is a paid advertisement. Carefully consider the investment objectives, risks, charges and expenses of the Fundrise Flagship Fund before investing. This and other information can be found in the Fund's prospectus. Read them carefully before investing.

When asked about Serve Robotics Inc. SERV , he said, "We’re not recommending companies that lose a ton of money because it’s just not the right time."

On Aug. 28, Serve Robotics announced closing of $20 million private placement & warrant exercise.

Read More: 

• Fractional real estate is the next big opportunity for building passive income — get started for just $100.
• With returns as high as 300%, it’s no wonder this asset is the investment choice of many billionaires. Uncover the secret.

Builders FirstSource, Inc. BLDR can "go higher," Cramer said, "This is precisely the kind of stock you should be buying at this stage in the cycle. Hold on."

On Aug. 6, Builders FirstSource reported second-quarter adjusted earnings per share of $3.50, beating the street view of $3.02. Quarterly sales of $4.456 billion missed the street view of $4.483 billion.

"Here’s the problem: it costs so much money to build the factories, they’re going to have to get a takeover to be able to do that," Cramer said about Viking Therapeutics, Inc. VXTX On July 24, Viking Therapeutics reported better-than-expected second-quarter EPS results.

A 9% Return In Just 3 Months

EquityMultiple's ‘Alpine Note — Basecamp Series' is turning heads and opening wallets. This short-term note investment offers investors a 9% rate of return (APY) with just a 3 month term and $5K minimum. The Basecamp rate is at a significant spread to t-bills. This healthy rate of return won't last long. With the Fed poised to cut interest rates in the near future, now could be the time to lock in a favorable rate of return with a flexible, relatively liquid investment option. 

What's more, Alpine Note — Basecamp can be rolled into another Alpine Note for compounding returns, or into another of EquityMultiple's rigorously vetted real estate investments, which also carry a minimum investment of just $5K. Basecamp is exclusively open to new investors on the EquityMultiple platform.

Looking for fractional real estate investment opportunities? The Benzinga Real Estate Screener features the latest offerings.